SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31

SCYNEXIS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$3.66−0.01 (-0.27%)

Close on Oct 19, 2026

Market cap: $43.28M
P/E (TTM): –
Dividend yield: –

SCYNEXIS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	19	20	21	2.93	3.26	2.63	3.75	8.57	9.67	140	140	136	136	5.53	5.09	4.16	3.12	1.80	13	13	12	12	0	0	0	0.06	0.12	0.19	0.25	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26
Research & Development	26	29	22	22	25	24	26	33	31	31	31	28	28	28	27	27	25	23	24	26	30	34	37	37	39	39	38	34	29	26	22	20	21	20	18	17	17	19	20	22
Selling, General & Admin	16	15	14	16	15	15	14	13	15	20	21	33	45	53	63	62	61	58	50	40	28	19	15	13	12	11	11	9.65	9.61	8.95	8.68	8.35	7.92	8.16	8.25	8.34	8.21	7.53	8.00	8.62
Operating Expenses	42	45	37	38	40	39	41	61	62	67	67	63	74	82	91	90	86	81	74	66	58	52	51	50	50	50	49	44	38	35	30	29	29	28	27	25	25	27	28	31
Operating Income	-23	-24	-16	-35	-37	-36	-37	-52	-52	74	73	73	62	-77	-86	-86	-83	-79	-61	-54	-46	-40	-51	-50	-50	-50	-49	-44	-38	-35	-30	-28	-28	-28	-26	-25	-25	-27	-28	-31
Interest Expense	0	0	0.17	0.38	0.60	0.79	0.83	0.84	0.84	1.89	3.13	4.44	5.60	5.59	5.20	4.65	4.29	3.51	2.66	2.00	1.31	1.19	1.18	1.07	0.94	0.83	0.99	1.19	1.43	1.61	1.63	1.59	1.52	1.49	1.46	1.43	1.06	0.70	0.35	–
Interest & Investment Income	2.09	1.92	2.18	2.61	3.18	3.80	4.29	4.79	5.04	4.64	3.95	3.28	2.55	1.99	1.42	0.73	0.21	0.03	0.02	0.02	0.02	0.05	0.19	0.31	0.48	0.68	0.81	0.95	1.04	1.08	0.97	0.82	0.67	0.48	0.39	0.33	0.27	0.23	0.19	–
Other Non-Operating Income	12	-0.13	7.47	9.35	17	8.76	16	16	17	28	-5.49	-1.06	-17	-15	18	3.25	30	36	25	4.45	-1.91	-15	-7.18	20	11	12	-4.79	-0.44	2.40	-3.50	11	6.36	-2.30	3.35	1.26	3.87	1.35	-1.05	-2.17	-4.35
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–
Pretax Income	–	–	-8.61	-25	-20	-27	-21	-36	-35	102	67	72	44	-91	-68	-82	-53	-43	-36	-49	-48	-55	-58	-30	-39	-38	-54	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	0	0.02	-0.37	-0.37	0.15	0.27	0.67	0.67	0.14	0	0	0	-4.70	-4.70	-4.75	-8.89	-3.09	-3.09	-3.04	-2.05	-3.15	-3.14	-3.14	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-30	-35
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0
Net Income incl. Noncontrolling Interests	-10	-25	-8.61	-25	-20	-27	-21	-36	-35	101	67	72	44	-91	-63	-78	-49	-34	-33	-46	-45	-53	-55	-27	-36	-38	-54	-37	-29	-31	-12	-22	-31	-24	-25	-21	-24	-28	-30	-35
Net Income	-10	-25	-8.61	-25	-20	-27	-21	-36	-35	101	67	72	44	-91	-63	-78	-49	-34	-33	-46	-45	-53	-55	-27	-36	-38	-54	-37	-29	-31	-12	-22	-31	-24	-25	-21	-24	-28	-30	–
Net Income to Common	–	–	–	–	–	-27	-21	-38	-37	100	67	73	45	-91	-63	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-2.15	-3.89	-1.36	-4.08	-3.20	-4.49	-3.52	-6.31	-6.15	16.73	11.20	12.05	7.41	-15.55	-11.76	-17.43	-12.63	-9.67	-10.00	-28.47	-27.59	-33.19	-37.51	-27.69	-39.85	-47.35	-78.75	-57.98	-45.74	-51.49	-23.93	-48.33	-73.93	-68.57	-74.17	-54.61	-68.21	-100.00	-126.40	-168.80
EPS (Diluted)(per share)	-2.15	-3.89	-1.36	-4.08	-3.20	-4.49	-3.52	-6.51	-6.35	15.73	11.12	11.25	6.61	-15.55	-11.76	–	–	–	–	-41.15	-42.91	-46.27	-50.19	-30.65	-40.01	-47.51	-78.91	-58.14	-45.74	-51.49	-23.93	-48.33	-73.93	-68.57	-78.97	-59.41	-73.01	-104.80	-126.40	-168.80
Shares Outstanding (Basic, Weighted)(shares)	7.69	6.29	6.24	6.18	6.14	6.10	6.06	6.04	6.02	6.00	5.98	5.97	5.96	5.82	5.33	4.69	4.03	3.49	3.30	2.84	2.34	1.84	1.34	1.16	1.00	0.85	0.70	0.64	0.62	0.60	0.55	0.49	0.43	0.36	0.33	0.32	0.31	0.27	0.24	0.21
Shares Outstanding (Diluted, Weighted)(shares)	7.69	6.29	6.24	6.18	6.14	6.10	6.06	5.97	5.95	5.99	6.05	6.04	6.02	5.82	5.33	4.70	4.09	3.56	3.30	2.81	2.36	1.85	1.34	1.24	1.03	0.89	0.70	0.68	0.62	0.60	0.55	0.49	0.43	0.36	0.33	0.32	0.31	0.27	0.24	0.21
EBITDA	–	–	–	–	–	–	-37	-52	-52	74	73	74	62	-76	-85	-85	-83	-78	-60	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -117.6%
Net margin: -53.3%
Return on equity, FY2025: -16.5%

Financial strength

Current ratio: 9.65
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 180.0%

Valuation

P/E ratio: –
Price to sales: 2.25
Price to book: 0.65
Dividend yield: –